SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-24-000056
Filing Date
2024-08-01
Accepted
2024-08-01 16:54:04
Documents
7
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 6-K q22024form6-k.htm 6-K 22463
2 EX-99.1 2024 SECOND QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsjune302024.htm EX-99.1 392680
3 EX-99.2 2024 SECOND QUARTER MD&A ex992-q22024mda.htm EX-99.2 243665
4 EX-99.3 Q2 2024 CERTIFICATION CEO ex993-q22024certificationx.htm EX-99.3 14355
5 EX-99.4 Q2 2024 CERTIFICATION CFO ex994-q22024certificationx.htm EX-99.4 14280
6 oncolyticslogotaglinebluea.jpg GRAPHIC 355294
7 oncolyticspipeline.jpg GRAPHIC 654350
  Complete submission text file 0001129928-24-000056.txt   2028788
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 241167569
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)